X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://endpts.com/agios-to-start-phiii-trial-with-pyrukynd-in-sickle-cell-disease/
https://www.fiercepharma.com/special-reports/2022-drug-approvals-after-aduhelm-fiasco-fda-endorsements-were-harder-come
https://www.globenewswire.com/news-release/2022/12/12/2571457/31990/en/Agios-Presents-Updated-PYRUKYND-mitapivat-Long-term-Extension-Data-Demonstrating-Sustained-Clinical-Benefits-in-Adults-with-Pyruvate-Kinase-PK-Deficiency-at-64th-ASH-Annual-Meeting.html
https://www.globenewswire.com/news-release/2022/12/10/2571417/31990/en/Agios-Presents-Updated-PYRUKYND-mitapivat-Data-Highlighting-Long-term-Safety-Profile-and-Durable-Improvement-in-Hemoglobin-and-Markers-of-Hemolysis-and-Ineffective-Erythropoiesis-i.html
https://www.ema.europa.eu/en/documents/overview/pyrukynd-epar-medicine-overview_en.pdf
https://www.globenewswire.com/news-release/2022/11/10/2553730/31990/en/PYRUKYND-mitapivat-Approved-in-the-EU-for-the-Treatment-of-Pyruvate-Kinase-PK-Deficiency-in-Adult-Patients.html
https://investor.agios.com/news-releases/news-release-details/agios-appoints-cecilia-jones-chief-financial-officer
https://www.globenewswire.com/news-release/2022/09/16/2517533/31990/en/Agios-Receives-Positive-CHMP-Opinion-for-PYRUKYND-mitapivat-for-the-Treatment-of-Pyruvate-Kinase-PK-Deficiency-in-Adult-Patients.html
https://www.globenewswire.com/news-release/2022/08/18/2501298/31990/en/Agios-Announces-Publication-of-Phase-3-ACTIVATE-T-Data-in-The-Lancet-Haematology-Demonstrating-Benefits-of-PYRUKYND-mitapivat-for-Adults-with-Pyruvate-Kinase-Deficiency.html
https://www.globenewswire.com/news-release/2022/08/11/2497249/31990/en/Agios-Announces-Publication-of-Phase-2-Data-in-The-Lancet-Demonstrating-Safety-and-Efficacy-of-PYRUKYND-mitapivat-in-Non-transfusion-dependent-%CE%B1-and-%CE%B2-Thalassemia.html
https://www.globenewswire.com/news-release/2022/06/13/2461017/0/en/CENTOGENE-and-Agios-Expand-Partnership-for-Clinical-Development-of-PYRUKYND-mitapivat-to-Treat-Children-With-Rare-Blood-Disease.html
https://www.globenewswire.com/news-release/2022/06/10/2460586/31990/en/Agios-Presents-New-Clinical-Data-Supporting-the-Benefits-of-PYRUKYND-mitapivat-Treatment-in-Adults-with-PK-Deficiency-at-European-Hematology-Association-Annual-Congress.html
https://www.globenewswire.com/news-release/2022/04/14/2422746/31990/en/Agios-Announces-Publication-of-Phase-3-ACTIVATE-Study-in-New-England-Journal-of-Medicine-Demonstrating-Benefits-of-PYRUKYND-mitapivat-for-Adults-with-Pyruvate-Kinase-Deficiency.html
https://www.statnews.com/2022/02/17/agios-wins-fda-approval-for-drug-to-treat-rare-form-of-anemia/
https://www.globenewswire.com/news-release/2021/12/13/2350961/31990/en/Agios-Presents-Mitapivat-Data-Highlighting-Long-term-Safety-Profile-and-Durable-Improvement-in-Hemoglobin-and-Markers-of-Hemolysis-in-Non-transfusion-dependent-%CE%B1-and-%CE%B2-Thalassemia-.html
https://www.globenewswire.com/news-release/2021/06/21/2250093/31990/en/Agios-Submits-New-Drug-Application-to-FDA-for-Mitapivat-for-Treatment-of-Adults-with-Pyruvate-Kinase-Deficiency.html
https://www.globenewswire.com/news-release/2020/11/12/2126102/0/en/Agios-Announces-FDA-Orphan-Drug-Designation-Granted-to-Mitapivat-for-Treatment-of-Sickle-Cell-Disease.html
https://investor.agios.com/news-releases/news-release-details/agios-first-class-pkr-activator-mitapivat-demonstrates-sustained
https://www.globenewswire.com/news-release/2020/06/08/2045185/0/en/Agios-Announces-FDA-Orphan-Drug-Designation-Granted-to-Mitapivat-for-Treatment-of-Thalassemia.html
Market Place
Share 
